Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6

  1. Yardley, D.A.
  2. Brufsky, A.
  3. Coleman, R.E.
  4. Conte, P.F.
  5. Cortes, J.
  6. Glück, S.
  7. Nabholtz, J.-M.A.
  8. O'Shaughnessy, J.
  9. Beck, R.M.
  10. Ko, A.
  11. Renschler, M.F.
  12. Barton, D.
  13. Harbeck, N.
Revista:
Trials

ISSN: 1745-6215

Año de publicación: 2016

Volumen: 17

Número: 1

Tipo: Errata

DOI: 10.1186/S13063-016-1195-6 GOOGLE SCHOLAR lock_openAcceso abierto editor

Objetivos de desarrollo sostenible